Opinion|Videos|June 24, 2024
Differential Diagnosis When Considering Hidradenitis Suppurativa in a Patient
Author(s)Iltefat Hamzavi, MD
A dermatologist provides clinical insights on differential diagnosis strategies when considering hidradenitis suppurativa in patients and the challenges associated with diagnosis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is in your differential diagnosis when considering hidradenitis suppurativa (HS) in a patient and how is this disease definitively diagnosed?
- Average delay in HS diagnosis has been found to be around 10 years. What do you think accounts for this and why is it imperative for patients with HS to be diagnosed sooner?
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5